Wednesday, July 18, 2018
Company News: Page (1) of 1 - 06/19/18 Email this story to a friend. email article Print this page (Article printing at page facebook
SynVivo's Tissue on Chip Platform Advances Mechanistic Understanding of Sepsis - New Data Presented at 41st Annual SHOCK Conference
Real-time quantitative detection of the cellular behavior under physiological flow conditions enabled mechanistic insight into sepsis and vascular damage. The platforms capability for rapid screening ...
(June 19, 2018)

HUNTSVILLE, Ala., June 19, 2018 /PRNewswire-PRWeb/ -- Multiple studies presented at the 2018 SHOCK conference in Scottsdale AZ report on the use of SynVivo's 3D tissue chip models for inflammation and sepsis mediated vascular damage. Protein kinase C-delta (PKC?) was shown to be important regulator of neutrophil-endothelium interactions during inflammation and sepsis. Dr. Laurie Kilpatrick and Dr. Mohammad Kiani's research team at Temple University led this collaborative research study based on SynVivo's Blood Brain Barrier and Inflammation model. Fariborz Soroush, Ph.D. student in Dr. Kiani and Dr. Kilpatrick's laboratories also received the new investigator award for his work on regulation of the PKC? using the SynVivo platform.

Results of this multi-year NIH funded research project highlighted the novelty and uniquness of the platform for predicting in vivo observations in humans and rodents.

Data presented showed:

  • In vitro replication of the in vivo microvascular networks, fluidic conditions and cell-cell interactions
  • Effect of varying shear conditions on the leukocyte-endothelium interactions comprising of rolling, adhesion and migration
  • Enhancement of vascular leakiness following sepsis mediated cytokine interactions by measurement of small molecule permeabilty across the endothelium.
  • Identification of PKC? as an important regulator of neutrophil and endothelium interactions in both the brain and lung microvessels. A PKC? inhibitor was found to be a novel therapeutic to protect from sepsis mediated vascular damage.

"Using the SynVivo platform was instrumental in elucidating mechanisms by which PKC? regulates the inflammatory cascade," said Dr. Kilpatrick. "The real-time monitoring capability in the SynVivo platform provides us a novel method to mimic in vivo neutrophil-endothelium interactions."

"We are excited that the SynVivo platform was key to these important discoveries in inflammation and advances in sepsis therapy," said Kapil Pant, PhD., President and CEO of Synvivo Inc. "Our 3D tissue on chip models are important tools that can potentially accelerate drug discovery and the development of safer targeted drugs for sepsis and other challenging human diseases."

About SynVivo's Inflammation model
The SynRAM™ 3D Inflammation Model from SynVivo has been developed to study the entire inflammation pathway in a realistic and dynamic environment. By recreating a histological slice of co-cultured tissue and/or tumor cells with a lumen of endothelial cells, the SynVivo platform delivers a physiologically realistic model that has been successfully validated against in vivo studies.

About SynVivo Inc.
SynVivo® is a microfluidic tissue–organ on chip platform that provides a biologically realistic microenvironment allowing real-time study of cellular behavior and drug delivery. Additional information can be found by visiting


Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc.,Medicine,Surgery,Medication,Science,Lifestyle,Communications Technology,Other,
Related Sites: DMN Newswire , ,   HTN - Health Technology Net
Related Newsletter: DMNForums ,   Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution

  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally -
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines